Your browser doesn't support javascript.
Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.
Boggiano, César; Eisinger, Robert W; Lerner, Andrea M; Anderson, James M; Woodcock, Janet; Fauci, Anthony S; Collins, Francis S.
  • Boggiano C; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (C.B.).
  • Eisinger RW; Office of the Director, National Institutes of Health, Bethesda, Maryland (R.W.E., J.M.A., F.S.C.).
  • Lerner AM; Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (A.M.L., A.S.F.).
  • Anderson JM; Office of the Director, National Institutes of Health, Bethesda, Maryland (R.W.E., J.M.A., F.S.C.).
  • Woodcock J; Office of the Commissioner, Food and Drug Administration, Silver Spring, Maryland (J.W.).
  • Fauci AS; Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (A.M.L., A.S.F.).
  • Collins FS; Office of the Director, National Institutes of Health, Bethesda, Maryland (R.W.E., J.M.A., F.S.C.).
Ann Intern Med ; 175(1): 119-126, 2022 01.
Article in English | MEDLINE | ID: covidwho-1497808
ABSTRACT
As the fourth wave of the SARS-CoV-2 pandemic encircles the globe, there remains an urgent challenge to identify safe and effective treatment and prevention strategies that can be implemented in a range of health care and clinical settings. Substantial advances have been made in the use of anti-SARS-CoV-2 antibodies to mitigate the morbidity and mortality associated with COVID-19. On 15 June 2021, the National Institutes of Health, in collaboration with the U.S. Food and Drug Administration, convened a virtual summit to summarize existing knowledge on anti-SARS-CoV-2 antibodies and to identify key unanswered scientific questions to further catalyze the clinical development and implementation of antibodies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article